Research Article

The Characterization of the Repertoire of Wheat Antigens and
Peptides Involved in the Humoral Immune Responses in Patients
with Gluten Sensitivity and Crohn’s Disease

Aristo Vojdani

Immunosciences Laboratory, Inc., 822 S. Robertson Boulevard, Suite 312, Los Angeles, CA 90035, USA

Correspondence should be addressed to Aristo Vojdani, drari@msn.com

Received 20 July 2011; Accepted 21 August 2011

Academic Editors: B. M. Stadler and P. E. Taylor

Copyright © 2011 Aristo Vojdani. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Intestinal T cells from gluten sensitivity/celiac disease patients respond to a heterogeneous array of peptides. Our study extended
this heterogeneity to humoral immune response to various wheat proteins and peptides in patients with gluten sensitivity or
Crohn’s disease. IgG and IgA antibodies in sera from those patients and healthy control subjects were measured against an array
of wheat antigens and peptides. In gluten-sensitive patients, IgG reacted most against transglutaminase, prodynorphin, wheat
extract, and α-, γ-, and ω-gliadin; IgA reacted most against wheat then transglutaminase, glutenin, and other peptides. In the sera
of Crohn’s disease patients, IgG reacted most against wheat and wheat germ agglutinin then transglutaminase, prodynorphin, α-, and
γ-gliadin; IgA reacted foremost against prodynorphin then transglutaminase and α-gliadin. These results showed a substantial
heterogeneity in the magnitude of IgG and IgA response against various wheat antigens and peptides. Measurements of IgG and
IgA antibodies against such an array of wheat peptides and antigens can enhance the sensitivity and specificity of serological assays
for gluten sensitivity and celiac disease and may also detect silent celiac disease or its overlap with inflammatory bowel disease.

1. Introduction

Despite the efforts of several laboratories to define relevant
wheat epitopes, the characterization of the complete repertoire of peptides involved in the pathogenesis of celiac disease and
associated disorders remains a daunting task because of the great heterogeneity of gluten proteins [1–4]. So far, several T cell stimulatory peptides from α-gliadin, γ-gliadin, and glutenins have been identified [1–4].

In a very recent study [5], intestinal T cells were isolated from 14 adults with celiac disease (CD) for recognition of 21 peptides derived from α-, γ-, ω-gliadins and glutenin. Results demonstrated that patients respond to a wide heterogeneous array of peptides; some recognized many peptides from single or multiple gliadin families, while others reacted to only one peptide. These results confirmed that a large number of gluten epitopes may be implicated in the development of gluten sensitivity, CD, and associated diseases. Indeed, a T cell line from a patient failed to recognize any of the 21 tested peptides. This suggests that other gliadin peptides and proteins are involved in the pathogenesis of gluten-sensitive enteropathy or CD [5]. T-cell responses of adult CD patients toward the overall 10 α-gliadin-derived peptides assayed indicated that they mainly focused on the 33-mer and its shorter forms, with the 17, 18, and 25-mer being the most frequently recognized by the T cell.

In contrast, responses elicited by γ-gliadin-derived peptides were less focused than those induced by α-gliadin-derived peptides, most likely reflecting their more diverse sequences. Furthermore, the great majority of patients reacted to at least one γ-gliadin peptide and an overall half-recognized DQ2-γ-I. This frequent recognition of γ-gliadin peptides by intestinal T cells from individuals with CD suggests that their contribution to CD pathogenesis may be greater than what we had thought. They also found that intestinal T cell lines were frequently and strongly stimulated by the ω-gliadin-derived peptide, DQ2ω-I [4–6].

Understanding the hierarchy and consistency of epitopes is important, as recent studies have shown that immunodominant epitopes not only can aid in a better diagnosis,
but also can have therapeutic applications for the induction of tolerance in several T cell-mediated diseases [7–9].

Conflicting data have been reported regarding the immunodominance of gluten peptides. For example, 50% of T cell lines derived from Dutch children and adults were reactive to peptides 33-mer and 13-mer [10]. This was consistent with the findings of Camarca et al., who also showed that 50% of T cell lines derived from CD patients recognized 33-mer of α-gliadin [5]. In contrast, 33-mer was universally recognized by HLA-DQ2 + in Norwegian patients recognized 33-mer of α-gliadin [5]. However, Camarca et al.’s study showed that there is a substantial heterogeneity in the intestinal T cell responses to α-, γ-, ω-gliadin and glutenin peptides and these peptides are the most active peptides that play a significant role in the pathogenesis of CD.

Having observed the heterogeneity of intestinal T-cell responses to gluten peptides, we wanted to see whether or not this immune reaction could similarly be extended to humoral immune responses, in particular IgG and IgA antibody production against the repertoire of antigens and peptides associated with gliadin in patients with gluten sensitivity as well as in patients with Crohn’s disease.

Crohn’s disease and ulcerative colitis fall under the classification of inflammatory bowel disease (IBD). They are triggered by environmental factors including food and microbial antigens [12]. The serologic response in Crohn’s disease includes antibodies against specific components of Saccharomyces cerevisiae, mycobacteria, bacteroides, and Escherichia coli [12–16]. In fact, the measurement of antibodies to baker’s and brewer’s yeasts directed against cell wall oligomannoside epitope (ASCA) have been proposed as a serological marker for Crohn’s disease [17]. These antibodies have a sensitivity of 60%–70% for differentiating Crohn’s disease from controls and a specificity of 80%–95% [12–18]. Due to overlapping symptomatology between celiac and Crohn’s disease, ASCA antibodies were also measured in a group of patients with CD. High incidences of ASCA were reported in patients with gluten sensitivity enteropathy (GSE). The IgG and IgA antibodies in the sera of GSE patients provided proof of a systemic response against Saccharomyces cerevisiae that suggested a breakdown in oral tolerance against the yeast antigens [19, 20]. The high prevalence of ASCA in patients with celiac disease encouraged us to expand the aim of this study from humoral immune response against a repertoire of wheat antigens and peptides in celiac disease to patients with Crohn’s disease.

2. Materials and Methods

A whole-wheat antigen was prepared by combining water-soluble and alcohol-soluble proteins. Different gliadin peptides including α-gliadin-33-mer, -17-mer, γ-gliadin-15-mer, ω-gliadin-17-mer, glutenin-21-mer, glutemorphin-16-mer, prodynorphin, transglutaminase (TG), and gliadin bound to TG, HPLC grade were synthesized by Bio-Synthesis Inc., (Lewisville, Tex, USA). Wheat germ agglutinin (WGA) was purchased from Sigma/Aldrich (Saint Louis, Mo, USA).

Forty-eight sera from healthy control subjects aged 18–65 were obtained from Innovative Research (Novi, Mich, USA). Commercially available sera of 24 patients with gluten sensitivity/celiac disease and 24 patients with Crohn’s disease were purchased from The Binding Site (San Diego, Calif, USA), Inova (San Diego, Calif, USA), Trina International Nanikon (Switzerland), Diamedix (Fl, USA), and Innovative Research (Novi, Mich, USA).

2.1. Measurement of IgG and IgA by ELISA. Antigen and peptides were dissolved in methanol at a concentration of 1.0 mg/mL then diluted 1:100 in 0.1 M carbonate-bicarbonate buffer, pH 9.5, and 100 μL of each of wheat, α-gliadin-33-mer, α-gliadin-17-mer, γ-gliadin-15-mer, ω-gliadin-17-mer, glutenin-21-mer, glutemorphin-16-mer and prodynorphin, gliadin-bound transglutaminase, transglutaminase (TG), and WGA were added to rows 1–11 of a microtiter plate. Row no. 12 was coated with 100 μL of 10 μg/mL of human serum albumin and used as control. Plates were incubated overnight at 4°C and then washed three times with 200 μL Tris-buffered saline (TBS) containing 0.05% Tween 20 (pH 7.4). The nonspecific binding of immunoglobulins was prevented by adding 200 μL of 2% bovine serum albumin (BSA) in TBS, and incubated overnight at 4°C. Plates were washed as mentioned previously, and then serum samples diluted 1:100 in 1% BSA in TBS containing 0.05% Tween 20 were added to duplicate wells and incubated for 1 hour at room temperature.

Plates were washed, and then alkaline phosphatase goat anti-human IgG or IgA F(ab′)2 fragments (KPI, Gaithersburg, MD) optimal dilution of 1:400 for IgA and 1:800 for IgG in 1% BSA-TBS were added to each appropriate well; plates were incubated for an additional hour at room temperature. After washing five times with TBS-Tween buffer, the enzyme reaction was started by adding 100 μL of 1 mg/mL para-nitrophenylphosphate in diethanolamine buffer containing 1 mM MgCl2 and sodium azide (pH 9.8). The reaction was stopped 45 mins later with 50 μL of 2 N NaOH. The optical density (OD) was read at 405 nm by the means of a microtiter reader. To exclude nonspecific binding, the ODs of the control wells coated with HSA (Row no. 12) were subtracted from all other wells. Sera from patients with celiac disease with known high titers of IgG and IgA against gliadin and transglutaminase peptides were used as positive controls.

2.2. Ethics. All samples were obtained from regulated and certified commercial providers who strictly maintain the anonymity of their sample donors and who are compliant with all required appropriate ethical practices.

2.3. Statistics. Statistics on Software (S.O.S.) version 2 was used for statistical analysis. Normal distribution was tested by the Kolmogorov-Smirnov one-sample test. One-way analysis of variance was performed by means of ANOVA. For post hoc analysis, the large sample Z-test was employed. Analysis of population variances was performed using the F-test. P values were used to determine levels of significance.
3. Results

3.1. Number of Patients and Tests. The data for IgG and IgA antibodies against an array of wheat antigens and peptides plus TG were derived from the sera of 48 healthy control subjects ages 18–65, 50% male and 50% female, with no history of GI disorder including gluten sensitivity and inflammatory bowel disease. For comparison, these antibodies were also measured in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn’s disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer and glutenin, glutenin, gluteomorphin, dynorphin, TG, and gliadin bound to TG. In addition, since WGA has a capacity to bind to different cells, inducing production of anti-WGA antibody [21, 22], we included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.

In healthy control subjects, we found moderate elevation (ELISA OD 0.4–1.0) of IgG antibody against glutenin-21-mer in 48 sera which, based on elevations in gliadin and transglutaminase IgG, IgA (24 sera) and anti-Saccharomyces IgA (24 sera) were classified with the possibility of gluten sensitivity/celiac disease and Crohn's disease, respectively. The degree of positivity of these sera were reactive against 1 to 8 different cells, inducing production of anti-WGA antibody [21, 22]. We included WGA in our antibody testing.
Table 1: Number of specimens with elevated antibodies against 11 tested antigens or peptides at the cutoff point of 0.39 OD.

|                  | Healthy controls | Gluten sensitive | Crohn’s | Healthy controls | Gluten sensitive | Crohn’s |
|------------------|------------------|-----------------|---------|------------------|-----------------|---------|
|                  | n = 48           | n = 24          | n = 24  | n = 48           | n = 24          | n = 24  |
| Wheat            | 9                | 19              | 13      | 54              | 16              | 67      | 5        | 10     | 24        | 100       | 6        | 25       |
| α-Gliadin 33     | 1                | 2               | 5       | 21              | 7               | 29      | 2        | 4      | 9         | 38        | 3        | 13       |
| α-Gliadin 17     | 0                | 0               | 8       | 33              | 4               | 17      | 9        | 19     | 9         | 38        | 3        | 13       |
| γ-Gliadin 15     | 0                | 0               | 11      | 46              | 9               | 38      | 0        | 0      | 12        | 50        | 8        | 33       |
| ω-Gliadin 17     | 1                | 2               | 10      | 42              | 5               | 21      | 2        | 4      | 11        | 46        | 3        | 13       |
| Glutenin 21      | 11               | 23              | 12      | 50              | 6               | 25      | 9        | 19     | 15        | 63        | 3        | 13       |
| Gluteomorphin    | 10               | 21              | 8       | 33              | 8               | 33      | 5        | 10     | 12        | 50        | 4        | 17       |
| Prodynorphin     | 0                | 0               | 14      | 58              | 11              | 46      | 4        | 8      | 17        | 71        | 10       | 42       |
| Gliadin + TG     | 1                | 2               | 8       | 33              | 8               | 33      | 0        | 0      | 14        | 58        | 2        | 8        |
| TG               | 0                | 0               | 16      | 67              | 10              | 42      | 0        | 0      | 20        | 83        | 8        | 33       |
| WGA              | 1                | 2               | 4       | 17              | 12              | 50      | 0        | 0      | 13        | 54        | 3        | 13       |

*P* values of *P* < 0.0001, with the least significant being *P* < 0.0411 for α-gliadin-17 (Table 3).

3.4. Detection of IgG and IgA Antibodies against Wheat and Various Gliadin Peptides in the Sera of Patients with Crohn's Disease. IgG and IgA antibodies against different wheat antigens and peptides, TG, gliadin bound to TG, and WGA were also measured in sera with IgA ASCA positive. For IgG antibody, at the 0.39 OD cutoff, 16 out of 24 (67%) of ASCA-positive specimens reacted with wheat, 12 specimens out of 24 reacted very strongly with WGA (50%), 11 with prodynorphin (46%), 10 with TG (42%), 9 with γ-gliadin-15 (38%), 8 with gluteomorphin and gliadin-TG (33%), 7 with α-gliadin-33 (29%), 6 with glutenin-21 (25%), 5 with ω-gliadin-17 (21%), and 4 with α-gliadin-17 (17%). Interestingly, all 12 WGA-reactive specimens also reacted with wheat antigens with or without the combination of gliadin peptides (Figure 3).

The mean ODs for IgG antibodies against various wheat and associated peptides and antigens in healthy controls were compared to those in patients with Crohn’s disease, obtaining the most significant *P* values with *P* < 0.0002 for prodynorphin, TG and WGA, as well as the least significant *P* values *P* < 0.4744 for glutenin, as are shown in Table 1.

In comparison to IgG, the prevalence of IgA-positive specimens in IgA ASCA-positive samples was much lower. Overall, 10 out of 24 specimens (42%) reacted with prodynorphin, 8/24 (33%) against TG and γ-gliadin-15, 6/24 (25%) against wheat, followed by gluteomorphin with 4/24 (17%), α-gliadin-33, α-gliadin-17, ω-gliadin-17, glutenin-21, and WGA with 3/24 (13%), and 2/24 for gliadin-TG (8%). Six (25%) of the ASCA-positive samples did not exhibit any IgA antibody against the 11 tested wheat or associated antigens and peptides (Figure 4).

Table 1: Number of specimens with elevated antibodies against 11 tested antigens or peptides at the cutoff point of 0.39 OD.

|                  | Healthy controls | Gluten sensitive | Crohn’s | Healthy controls | Gluten sensitive | Crohn’s |
|------------------|------------------|-----------------|---------|------------------|-----------------|---------|
|                  | n = 48           | n = 24          | n = 24  | n = 48           | n = 24          | n = 24  |
| Wheat            | 9                | 19              | 13      | 54              | 16              | 67      | 5        | 10     | 24        | 100       | 6        | 25       |
| α-Gliadin 33     | 1                | 2               | 5       | 21              | 7               | 29      | 2        | 4      | 9         | 38        | 3        | 13       |
| α-Gliadin 17     | 0                | 0               | 8       | 33              | 4               | 17      | 9        | 19     | 9         | 38        | 3        | 13       |
| γ-Gliadin 15     | 0                | 0               | 11      | 46              | 9               | 38      | 0        | 0      | 12        | 50        | 8        | 33       |
| ω-Gliadin 17     | 1                | 2               | 10      | 42              | 5               | 21      | 2        | 4      | 11        | 46        | 3        | 13       |
| Glutenin 21      | 11               | 23              | 12      | 50              | 6               | 25      | 9        | 19     | 15        | 63        | 3        | 13       |
| Gluteomorphin    | 10               | 21              | 8       | 33              | 8               | 33      | 5        | 10     | 12        | 50        | 4        | 17       |
| Prodynorphin     | 0                | 0               | 14      | 58              | 11              | 46      | 4        | 8      | 17        | 71        | 10       | 42       |
| Gliadin + TG     | 1                | 2               | 8       | 33              | 8               | 33      | 0        | 0      | 14        | 58        | 2        | 8        |
| TG               | 0                | 0               | 16      | 67              | 10              | 42      | 0        | 0      | 20        | 83        | 8        | 33       |
| WGA              | 1                | 2               | 4       | 17              | 12              | 50      | 0        | 0      | 13        | 54        | 3        | 13       |

*P* values: 0.0004 for IgG versus patients, 0.0017 for healthy controls versus patients, 0.0001 for IgA versus patients, 0.1262 for healthy controls versus patients.

The mean OD of IgA antibody against 11 tested wheat-associated antigens and peptides in the sera of patients with Crohn's disease are also shown in Table 3. Differences between the mean ODs of IgA antibody against 3 out of 11 tested antigens in healthy controls versus patients with Crohn’s disease were significant (*P* < 0.0035 for prodynorphin, *P* < 0.0044 for γ-gliadin-15, *P* < 0.0047 for TG (Table 2)).

The overall number and percentage of healthy controls versus patients’ sera with elevated IgG and IgA antibody against wheat antigens and associated peptides are shown in Table 1. As shown in this table, the difference in percentage of individuals with elevated antibodies in healthy controls versus patients is very significant (*P* < 0.0004 for IgG antibody in the gluten-sensitive/celiac group, *P* < 0.0017 for IgG in the Crohn’s group, and *P* < 0.0001 for IgA antibody in the gluten-sensitive group). While there is a significant overlap between IgG and IgA antibodies in both patients’ groups, the percentage of IgA-reactive specimens against various tested antigens was the most significant in the gluten-sensitive group, followed by IgG presence in both the gluten-sensitive and Crohn’s disease groups, with IgA reactivity against these antigens being the least significant in patients with Crohn’s disease (Table 1).

4. Discussion

A number of gluten peptides with a capacity to stimulate intestinal T-helper cells have been identified in CD patients by many researchers (2–6, 10, and 23–26). In a very recent study T cells isolated from CD patients were screened for recognition of 21 different peptides from α-, γ-, ω-gliadins and glutenins [5]. It was demonstrated that intestinal T cells from CD patients responded to a wide and heterogeneous
Table 2: IgG antibody expressed as optical density (OD) against wheat and all gliadin, glutenin peptides, exorphins, gliadin-transglutaminase, transglutaminase, and WGA in healthy control subjects and patients with gluten sensitivity and Crohn’s disease.

|                  | Wheat (OD) | α-Gliadin 33 (OD) | α-Gliadin 17 (OD) | γ-Gliadin 15 (OD) | ω-Gliadin 17 (OD) | Glutemin 21 (OD) | Glutemorphin (OD) | Pro-dynorphin (OD) | Gliadin + transglut (OD) | Transglut (OD) | WGA (OD) |
|------------------|------------|-------------------|-------------------|-------------------|-------------------|------------------|-------------------|-------------------|----------------------|----------------|----------|
| **Control mean ± SD** | 0.27 ± 0.12 | 0.09 ± 0.09 | 0.08 ± 0.09 | 0.07 ± 0.08 | 0.13 ± 0.10 | 0.29 ± 0.18 | 0.25 ± 0.18 | 0.09 ± 0.08 | 0.06 ± 0.09 | 0.08 ± 0.10 | 0.10 ± 0.11 |
| **Gluten Sensitive Patient mean ± SD** | 0.45 ± 0.38 | 0.18 ± 0.37 | 0.38 ± 0.53 | 0.62 ± 0.60 | 0.37 ± 0.52 | 0.55 ± 0.52 | 0.35 ± 0.49 | 0.64 ± 0.57 | 0.40 ± 0.50 | 0.85 ± 0.76 | 0.36 ± 0.66 |
| **P values**     | 0.0155     | 0.1278           | 0.0053           | 0.0001           | 0.0167           | 0.0104          | 0.1565          | 0.0001           | 0.0013              | 0.0001        | 0.0314   |
| **Crohn’s patient Mean ± SD** | 0.71 ± 0.57 | 0.23 ± 0.35 | 0.22 ± 0.36 | 0.47 ± 0.53 | 0.26 ± 0.43 | 0.29 ± 0.39 | 0.24 ± 0.34 | 0.59 ± 0.58 | 0.34 ± 0.43 | 0.63 ± 0.65 | 1.00 ± 1.06 |
| **P values**     | 0.0005     | 0.0306           | 0.0341           | 0.0006           | 0.0692           | 0.4744          | 0.4621          | 0.0002           | 0.0021              | 0.0002        | 0.0002   |
Table 3: IgA antibody expressed as optical density (OD) against wheat and all gliadin, glutenin peptides, exorphins, gliadin-transglutaminase, transglutaminase, and WGA in healthy control subjects and patients with celiac and Crohn’s disease.

|                  | Wheat (OD) | α-Gliadin 33 (OD) | α-Gliadin 17 (OD) | γ-Gliadin 15 (OD) | ω-Gliadin 17 (OD) | Gluten 21 (OD) | Glutemorphin (OD) | Prodynorphin (OD) | Gliadin + transglut (OD) | Transglut (OD) | WGA (OD) |
|------------------|------------|-------------------|------------------|------------------|------------------|----------------|------------------|------------------|--------------------------|--------------|---------|
| Control mean ± SD| 0.23 ± 0.15| 0.11 ± 0.09       | 0.25 ± 0.26      | 0.11 ± 0.06      | 0.13 ± 0.08      | 0.23 ± 0.23   | 0.19 ± 0.16      | 0.13 ± 0.10      | 0.06 ± 0.06               | 0.10 ± 0.07 | 0.11 ± 0.07 |
| Gluten sensitive Patient mean ± SD | 0.89 ± 0.30 | 0.28 ± 0.37       | 0.45 ± 0.51      | 0.71 ± 0.60      | 0.52 ± 0.54      | 0.66 ± 0.51   | 0.45 ± 0.48      | 0.84 ± 0.56      | 0.61 ± 0.51               | 1.01 ± 0.60 | 1.11 ± 0.95 |
| P values          | 0.0001     | 0.0195            | 0.0411           | 0.0001           | 0.0009           | 0.0003        | 0.0078           | 0.0001           | 0.0001                   | 0.0001      | 0.0001  |
| Crohn’s patient Mean ± SD | 0.29 ± 0.50 | 0.13 ± 0.35       | 0.15 ± 0.33      | 0.39 ± 0.49      | 0.11 ± 0.29      | 0.15 ± 0.28   | 0.14 ± 0.28      | 0.44 ± 0.50      | 0.12 ± 0.25               | 0.52 ± 0.73 | 0.40 ± 0.81 |
| P values          | 0.2777     | 0.3859            | 0.0935           | 0.0044           | 0.3312           | 0.0992        | 0.2106           | 0.0035           | 0.1544                   | 0.0047      | 0.0517  |
array of peptides [5]. In some patients, many peptides from the α-gliadin family were recognized, while in others, only one peptide caused lymphocyte stimulation and interferon-γ production. Furthermore, T-cell lines from one particular patient did not recognize any of the 21 tested peptides at all, while, overall, 86% of CD patients recognized a different array of peptides. It was concluded that other gliadin peptides not tested in the study could be relevant in some CD patients [5].

Although all these findings showed great heterogeneity in immunogenicity of gluten peptides for lymphocyte proliferation and IFN-γ production [2–6, 23–26], no attempt was made to measure heterogeneity in antibody response to various gluten and overall wheat proteins.
and peptides. In the present study, we screened the sera of patients with gluten-sensitivity/celiac disease and Crohn’s disease for the presence of IgG and IgA antibodies against both alcohol- and water-soluble components of wheat, α-gliadin-33-mer, -17-mer, γ-gliadin-15-mer, ω-gliadin-17-mer, and glutenin-21-mer.

The second category of peptides consisted of the opioids. Such peptides are called exorphins because of their exogenous origin and morphine-like characteristics. In some individuals, dietary exorphins are resistant to intestinal and enterobacterial proteinases; thus, glucomorphins and dynorphins may be absorbed from the gut lumen into the bloodstream. Consequently, an immune response against the opioid peptides can result in peptide antibody production and regulation of opioid receptor binding capability [27, 28].

Thirdly, lectins were incorporated into this antibody array. WGAs are lectins, or carbohydrate-binding proteins, with a capacity to bind to many cells and tissue antigens,
including intestinal brush borders. Lectins, bound to intestinal and other cell membranes, are known to induce toxic damage, inflammation, and autoimmunity [21, 22, 29].

Finally, earlier studies showed that gluten-sensitive patients develop IgG and IgA antibodies to gliadin and to the autoantigen called transglutaminase [30, 31]. These articles demonstrated that gliadin is the preferred substrate of transglutaminase and suggested that the interaction of gliadin and TG may result in the creation of new antigenic complexes [31, 32]. Indeed, in a different study [33], it was shown that at high molar excess gliadin peptides bind to six lysine residues of TG, forming isopeptide bonds. However, despite this demonstration of the molecular characterization of covalent complexes between tissue TG and gliadin peptides and discussion about its relevance in celiac disease, no attempt was made to measure antibodies against different gliadin peptides and their complex formation with TG. Therefore, we extended the measurement of IgG and IgA antibodies against this gliadin and TG complex as well.

Similar to intestinal T-cell response, we demonstrated that humoral immune response to various wheat antigens and associated peptides are largely heterogeneous [5, 23]. Consistent with previous studies conducted with intestinal (T-cell) response against a heterogeneous array of wheat glutenin and α-, γ-, α-gliadins, our results with IgG- and IgA-specific antibodies demonstrate that both sera with gluten-sensitivity/celiac disease and Crohn's disease and, to a much lesser degree, sera from healthy controls respond to a heterogeneous array of peptides and antigens. In some cases, IgG and IgA antibodies were detected against wheat antigens alone or in combination with α-, γ-, and ω-gliadins and glutenin peptides, while in others, IgG or IgA were detected against one or more peptides without reacting to wheat antigens. This lack of humoral immune response to water- and alcohol-soluble components of wheat indicates that digestion of wheat proteins into various peptides and their deamidation by TG plays a significant role in their antigenicity. The selective deamidation of gliadin peptides and their complex formation with TG make them more specific B cell epitopes, which result in first IgA and then IgG production [31–33]. Indeed, IgA was detected in the great majority of patients with CD against wheat antigens (100%), followed by immune reaction against prodynorphin (71%), glutenin-21 (62%), gliadin-TG (58%), WGA (52%), and against other proteins and peptides between 37% and 50%, as seen in Table 1.

In comparison with IgA, IgG was detected in the sera of celiac disease patients most prominently against TG, followed by prodynorphin, wheat extract, and then glutenin-21 mer (Table 1). The current methodology for diagnosing celiac disease is based on measuring IgG and IgA antibodies against gliadin and TG [30–38]. The specificity and sensitivity of these assays in patients with CD who exhibit abnormal histology (villous atrophy or flat mucosa) varies between 85% and 100% [34–38]. However, this specificity and sensitivity have not been established for patients with gluten sensitivity and patients with silent or atypical celiac disease who may have GI symptoms but normal villi. Autoantibodies can be detected in various diseases for a long period during which no clinical symptoms are present [39, 40]. In fact, in many studies, a direct relationship has now been shown between antibody levels and severity of diseases [41–44]. Similar to these autoimmune diseases, in population screening for celiac disease, antibodies were detected persistently over a 4-year period [45]. Interestingly, nine of the subjects with transient antibodies had villous atrophy, suggesting that this feature develops after chronic immune activation including T-cell response, cytokines and antibody production [39, 45, 46]. Thus, according to these authors, as with type 1 diabetes and thyroiditis, a substantial proportion have transient autoantibodies, but when the autoantibodies persist, the risk of progression to clinical celiac disease is high. As a result, celiac disease-associated autoantibodies are now widely used for disease prediction and diagnosis. Indeed, removal of the antigen, gluten, is currently the therapy of choice for celiac disease [34]. However, due to long-term immunoreactions and severe tissue destruction, gluten-free diets do not result in complete normalization of duodenal lesions in a majority of patients with celiac disease [47]. Therefore, early detection of biomarkers associated with chronic immune activation may result in timely intervention and the prevention of villous atrophy.

Since earlier studies performed on intestinal T cells [5, 23–26] showed that response to various gliadin and other associated peptides is heterogeneous, we believe that the application of IgG and IgA antibodies against an array of antigens and peptides that includes α-, γ-, and ω-gliadins, glutenin, WGA, glotemorphin, prodynorphins, TG, and gliadin-bound TG can not only enhance the detection of celiac disease but may also assist in the early detection of atypical and silent celiac disease.

Atypical celiac disease, which presents with few or no symptoms, is largely responsible for the increased prevalence of CD today [48]. Celiac disease may be silent or atypical, but it is still a serious disorder [49]. It has been shown that for every recognized case of CD, there are 8 that remain undiagnosed [49], and undiagnosed CD can have very serious consequences. The consequences of undiagnosed CD include not only underachievement [50] and a 5-fold higher risk of non-Hodgkin's lymphoma [51] but also a 4-fold increase in all-cause mortality [52].

Due to some symptomatology overlap between Crohn's disease and CD [12], we applied IgG and IgA measurements against various wheat antigens and associated peptides to the sera of patients with Crohn's disease who were positive for ASCA to examine the occurrence of CD with IBD. In comparison with healthy controls, IgG antibody in the sera of patients with Crohn's disease was found to be highly elevated, foremost against wheat extract (67%), secondly against WGA (50%), prodynorphin third (46%), and then TG (42%), with P values being significant against 9 out of 11 tested antigens (Tables 2 and 3). The differences in IgA antibody response against the same array of wheat antigens and peptides used in the study were less significant (Tables 2 and 3), only being significant against 4 of the antigens or peptides: prodynorphin, α-gliadin-15, TG, and WGA.
Based on these findings, we propose that for the early detection of immune activation in atypical or silent celiac disease and patients with IBD or Crohn's disease, IgG and IgA antibodies be measured not only against α-gliadin and TG, but also against water- and alcohol-soluble components of wheat, WGA, ω- and γ-gliadin, glutenin, glutenomorphin, and gliadin bound to TG. This may increase the sensitivity and specificity of assays for sufferers not only of classical celiac disease, but also atypical or silent CD as well as patients with IBD who may suffer from gluten sensitivities.

It can be speculated that in addition to gluten-free diets for patients with CD who are ASCA positive, yeast-free diets may also be recommended. If the yeast-free diet along with the gluten-free diet helps patients to get well, then this practice may become an acceptable alternative method of therapy. Further studies are needed in order to compare and measure T-cell and antibody response to these various antigens and peptides simultaneously in patients with normal and abnormal villi.

**Abbreviations**

ASCA: Anti-Saccharomyces cerevisiae mannan antibodies
BSA: Bovine serum albumin
CD: Celiac disease
ELISA: Enzyme-linked immunosorbent assay
F(ab′)2: Fragment antigen-binding
HSA: Human serum albumin
IBD: Inflammatory bowel disease
IFN-γ: Interferon gamma
Ig: Immunoglobulin
OD: Optical density
TBS: Tris-buffered saline
TG: Transglutaminase
WGA: Wheat germ agglutinin.

**Disclosure**

A. Vojdani is the co-owner and CEO of Immunosciences Lab., Inc., Los Angeles, Calif, USA.

**Acknowledgment**

The author would like to thank Joel Bautista for the preparation of this paper.

**References**

[1] M. Silano and M. De Vincenzi, “Bioactive antinutritional peptides derived from cereal prolamins: a review,” Die Nahrung, vol. 43, no. 3, pp. 175–184, 1999.

[2] H. Arentz-Hansen, R. Körner, Ø. Molberg et al., “The intestinal T cell response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase,” The Journal of Experimental Medicine, vol. 191, no. 4, pp. 603–612, 2000.

[3] H. Arentz-Hansen, S. N. Mcadam, O. Molberg et al., “Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues,” Gastroenterology, vol. 123, no. 3, pp. 803–809, 2002.

[4] S. Tollefsen, H. Arentz-Hansen, B. Fleckenstein et al., “HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease,” The Journal of Clinical Investigation, vol. 116, no. 8, pp. 2226–2236, 2006.

[5] A. Camarca, R. P. Anderson, G. Mamone et al., “Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease,” Journal of Immunology, vol. 182, no. 7, pp. 4158–4166, 2009.

[6] C. L. Vanderlugt and S. D. Miller, “Epitope spreading in immune-mediated diseases: implications for immunotherapy,” Nature Reviews Immunology, vol. 2, no. 2, pp. 85–95, 2002.

[7] W. L. G. Oldfield, A. B. Kay, and M. Larché, “Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects,” Journal of Immunology, vol. 167, no. 3, pp. 1734–1739, 2001.

[8] M. D. Leech, C. Y. Chung, A. Culshaw, and S. M. Anderton, “Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis,” European Journal of Immunology, vol. 37, no. 12, pp. 3576–3581, 2007.

[9] M. Larché and D. C. Wraith, “Peptide-based therapeutic vaccines for allergic and autoimmune diseases,” Nature Medicine, vol. 11, no. 4, pp. S69–S76, 2005.

[10] W. Vader, Y. Kooy, P. Van Veelen et al., “The Gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides,” Gastroenterology, vol. 122, no. 7, pp. 1729–1737, 2002.

[11] L. Shan, Ø. Molberg, I. Parrot et al., “Structural basis for gluten intolerance in celiac sprue,” Science, vol. 297, no. 5590, pp. 2275–2279, 2002.

[12] Z. Barta, I. Csipó, G. G. Szabó, and G. Szegedi, “Sero-reactivity against Saccharomyces cerevisiae in patient with Crohn's disease and celiac disease,” World Journal of Gastroenterology, vol. 9, no. 10, pp. 2308–2312, 2003.

[13] R. M. R. Barnes, S. Allan, C. H. Taylor-Robinson, R. Finn, and P. M. Johnson, “Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?” International Archives of Allergy and Applied Immunology, vol. 92, no. 1, pp. 9–15, 1990.

[14] P. Knollach, B. H. Park, and R. Cunninham, “Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease,” Gastroenterology, vol. 92, no. 2, pp. 479–485, 1987.

[15] J. Main, H. McKenzie, G. R. Yaman et al., “Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease,” British Medical Journal, vol. 297, no. 6656, pp. 1105–1106, 1988.

[16] M. H. Giaffer, A. Clark. and C. D. Holdsworth, “Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance,” Gut, vol. 33, no. 8, pp. 1071–1075, 1992.

[17] J. F. Quinton, B. Sendid, D. Reumaux et al., “Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role,” Gut, vol. 42, no. 6, pp. 788–791, 1998.

[18] A. Yang, Y. Chen, E. Scherl, A. I. Neugut, G. Bhagat, and P. H. R. Green, “Inflammatory bowel disease in patients with celiac disease,” Inflammatory Bowel Diseases, vol. 11, no. 6, pp. 528–532, 2005.
[19] S. Strobel and A. M. Mowat, “Immune responses to dietary antigens: oral tolerance,” *Immunology Today*, vol. 19, no. 4, pp. 173–181, 1998.

[20] J. G. M. C. Damoiseaux, B. Bouten, A. M. L. W. Linders et al., “Diagnostic value of anti-*Saccharomyces cerevisiae* and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease,” *Journal of Clinical Immunology*, vol. 22, no. 5, pp. 281–288, 2002.

[21] L. M. Sollied, J. Kolberg, H. Scott, J. Ek, O. Fausa, and P. Brantzäg, “Antibodies to wheat germ agglutinin in celiac disease,” *Clinical and Experimental Immunology*, vol. 63, no. 1, pp. 95–100, 1986.

[22] N. Kitano, T. Tanimoto, T. Ida et al., “Detection of antibodies against wheat germ agglutinin bound glycoproteins on the islet-cell membrane,” *Diabetic Medicine*, vol. 5, no. 2, pp. 139–144, 1988.

[23] J. A. Tye-Din, J. A. Stewart, J. A. Dromey et al., “Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease,” *Science Translational Medicine*, vol. 2, no. 41, Article ID 41ra51, 2010.

[24] H. Sjöström, K. E. A. Lundin, O. Molberg et al., “Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition,” *Scandinavian Journal of Immunology*, vol. 48, no. 2, pp. 111–115, 1998.

[25] R. P. Anderson, D. A. van Heel, J. A. Tye-Din et al., “T cells in peripheral blood after gluten challenge in coeliac disease,” *Gut*, vol. 54, no. 9, pp. 1217–1223, 2005.

[26] Y. Van de Wal, Y. M. C. Kooy, P. van Veelen et al., “Glutenin is involved in the gluten-driven mucosal T cell response,” *European Journal of Immunology*, vol. 29, no. 10, pp. 3133–3139, 1999.

[27] G. Macé, M. Jaume, C. Blanpied et al., “Anti-μ-opioid-receptor IgG antibodies are commonly present in serum from healthy blood donors: evidence for a role in apoptotic immune cell death,” *Blood*, vol. 100, no. 9, pp. 3261–3268, 2002.

[28] A. Vojdani, T. O’Bryan, J. A. Green et al., “Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism,” *Nutritional Neuroscience*, vol. 7, no. 3, pp. 151–161, 2004.

[29] E. Köttgen, F. Kluge, B. Volk, and W. Gerok, “The lectin properties of gluten as the basis of the pathomechanism of gluten-sensitive enteropathy,” *Klinische Wochenschrift*, vol. 61, no. 2, pp. 111–112, 1983.

[30] S. A. McMillan, D. J. Haughton, J. D. Biggart, J. D. Edgar, K. G. Porter, and T. A. McNeill, “Predictive value for coeliac disease of antibodies to gliadin, endomysium, and jejenum in patients attending for jejunal biopsy,” *British Medical Journal*, vol. 303, no. 6811, pp. 1163–1165, 1991.

[31] W. Dieterich, T. Ehnis, M. Bauer et al., “Identification of tissue transglutaminase as the autoantigen of celiac disease,” *Nature Medicine*, vol. 3, no. 7, pp. 797–801, 1997.

[32] M. N. Marsh, “Transglutaminase, gluten and celiac disease: food for thought,” *Nature Medicine*, vol. 3, no. 7, pp. 725–726, 1997.

[33] B. Fleckenstein, S. W. Qiao, M. R. Larsen, G. Jung, P. Roepstorff, and L. M. Solliid, “Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides,” *Journal of Biological Chemistry*, vol. 279, no. 17, pp. 17607–17616, 2004.

[34] D. Agardh, K. Lynch, C. Brundin, S. A. Ivarsson, A. Lernmark, and C. M. Cilìo, “Reduction of tissue transglutaminase autoantibody levels by gluten-free diet is associated with changes in subsets of peripheral blood lymphocytes in children with newly diagnosed coeliac disease,” *Clinical and Experimental Immunology*, vol. 144, no. 1, pp. 67–75, 2006.

[35] M. Ankelo, V. Kleimola, S. Simell et al., “Antibodies to deamidated gliadin peptide show high specificity and parallel antibodies to tissue transglutaminase in developing coeliac disease,” *Clinical and Experimental Immunology*, vol. 150, no. 2, pp. 285–293, 2007.

[36] K. Kaukinen, P. Collin, K. Laurila, T. Kaartinen, J. Partanen, and M. Mäki, “Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit,” *Scandinavian Journal of Gastroenterology*, vol. 42, no. 12, pp. 1428–1433, 2007.

[37] D. Basso, G. Guariso, P. Fogar et al., “Antibodies against synthetic deamidated gliadin peptides for celiac disease diagnosis and follow-up in children,” *Clinical Chemistry*, vol. 55, no. 1, pp. 150–157, 2009.

[38] P. Toftedal, C. Nielsen, J. T. Madsen, K. Tilstad, S. Husby, and S. T. Lillevang, “Positive predictive value of serological diagnostic measures in celiac disease,” *Clinical Chemistry and Laboratory Medicine*, vol. 48, no. 5, pp. 685–691, 2010.

[39] D. Leslie, P. Lipsky, and A. Louis Notkins, “Autoantibodies as predictors of disease,” *The Journal of Clinical Investigation*, vol. 108, no. 10, pp. 1417–1422, 2001.

[40] A. L. Notkins, “New predictors of disease,” *Scientific American*, vol. 296, no. 3, pp. 72–79, 2007.

[41] R. D. G. Leslie, M. A. Atkinson, and A. L. Notkins, “Autoantigens IA-2 and GAD in type I (insulin-dependent) diabetes,” *Diabetologia*, vol. 42, no. 1, pp. 3–14, 1999.

[42] C. M. Dayan and G. H. Daniels, “Chronic autoimmune thyroiditis,” *The New England Journal of Medicine*, vol. 335, no. 2, pp. 99–107, 1996.

[43] C. Betterle, M. Volpato, B. R. Smith et al., “Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison’s disease,” *Journal of Clinical Endocrinology and Metabolism*, vol. 82, no. 3, pp. 939–942, 1997.

[44] A. Vojdani, “Antibodies as predictors of autoimmune diseases and cancer,” *Expert Opinion on Medical Diagnostics*, vol. 2, no. 6, pp. 593–605, 2008.

[45] S. D. Johnston, R. G. P. Watson, S. A. McMillan, A. E. Evans, and A. H. G. Love, “Serological markers for coeliac disease: changes with time and relationship to enteropathy,” *European Journal of Gastroenterology and Hepatology*, vol. 10, no. 3, pp. 259–264, 1998.

[46] W. Dickey, S. A. Mcmillan, and D. F. Hughes, “Identification of coeliac disease in primary care,” *Clinical and Experimental Immunology*, vol. 33, no. 5, pp. 491–493, 1998.

[47] A. Lancini, F. Lanzarotto, V. Villanacci et al., “Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet,” *Alimentary Pharmacology & Therapeutics*, vol. 29, no. 12, pp. 1299–1308, 2009.

[48] E. W. Guthrie and M. A. Gettis, “Celiac disease: more common than once thought,” *U.S. Pharmacist*, vol. 33, no. 12, pp. 24–29, 2008.

[49] M. Kumar and G. W. Rutecki, “Atypical celiac disease: could you be missing this common problem?” *Consultant*, vol. 50, no. 3, pp. 1–11, 2010.
[50] M. A. Verkasalo, O. T. Raitakari, J. Viikari, J. Marniemi, and E. Savilahti, “Undiagnosed silent coeliac disease: a risk for underachievement?” Scandinavian Journal of Gastroenterology, vol. 40, no. 12, pp. 1407–1412, 2005.

[51] Y. Gao, S. Y. Kristinsson, L. R. Goldin, M. Björkholm, N. E. Caporaso, and O. Landgren, “Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association,” Gastroenterology, vol. 136, no. 1, pp. 91–98, 2009.

[52] A. Rubio-Tapia, R. A. Kyle, E. L. Kaplan et al., "Increased prevalence and mortality in undiagnosed celiac disease," Gastroenterology, vol. 137, no. 1, pp. 88–93, 2009.